Innovent Says China’s NMPA Accepts Sintilimab Application for Advanced Melanoma
Innovent said China’s National Medical Products Administration accepted a new indication application for sintilimab to treat advanced melanoma.
Innovent said China’s National Medical Products Administration accepted a new indication application for sintilimab to treat advanced melanoma.